Ensign Peak Advisors Inc Cuts Stake in Elanco Animal Health Incorporated $ELAN

Ensign Peak Advisors Inc reduced its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 11.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 142,360 shares of the company's stock after selling 18,000 shares during the period. Ensign Peak Advisors Inc's holdings in Elanco Animal Health were worth $2,033,000 at the end of the most recent reporting period.

• Bullish or Bearish? Vetting Animal Health Care Stocks

A number of other hedge funds have also recently made changes to their positions in the business. Nuveen LLC bought a new position in shares of Elanco Animal Health during the 1st quarter valued at $115,212,000. Dimensional Fund Advisors LP boosted its position in Elanco Animal Health by 14.3% during the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock valued at $214,875,000 after buying an additional 2,563,740 shares during the period. Jennison Associates LLC grew its stake in shares of Elanco Animal Health by 322.0% during the second quarter. Jennison Associates LLC now owns 3,234,717 shares of the company's stock valued at $46,192,000 after buying an additional 2,468,122 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after buying an additional 2,445,872 shares during the period. Finally, ASR Vermogensbeheer N.V. purchased a new position in shares of Elanco Animal Health in the first quarter worth about $23,744,000. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Trading Down 0.3%

Elanco Animal Health stock opened at $23.36 on Friday. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $23.70. The business's fifty day moving average is $21.24 and its 200 day moving average is $17.35. The stock has a market capitalization of $11.61 billion, a PE ratio of 389.36, a price-to-earnings-growth ratio of 3.17 and a beta of 1.71. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23.

• Zoetis Declares New Dividend, Hinting At Undervaluation

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping analysts' consensus estimates of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.Elanco Animal Health's revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. On average, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on ELAN shares. Argus upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating and set a $25.00 price objective for the company in a report on Wednesday, November 19th. KeyCorp started coverage on Elanco Animal Health in a research note on Friday, November 21st. They set an "overweight" rating and a $27.00 price objective for the company. Zacks Research cut Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, November 6th. Wall Street Zen upgraded Elanco Animal Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 15th. Finally, UBS Group upped their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a "buy" rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $21.56.

• 2 Contrarian Stock Picks With Major Upside

View Our Latest Stock Report on ELAN

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Featured Articles

• Five stocks we like better than Elanco Animal Health
• Utilities Stocks Explained – How and Why to Invest in Utilities
• Keysight Technologies' Surge: The Market Wakes Up to This AI Play
• What Are Dividend Challengers?
• Is American Express the Credit Stock For a K-Shaped Economy?
• What is a Bond Market Holiday? How to Invest and Trade
• Powering Up: How a Credit Upgrade Fuels Vistra’s AI Ambitions

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elanco Animal Health Right Now?

Before you consider Elanco Animal Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.

While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here